Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of EVG/FTC/TDF/GS-9350 versus ritonavir-boosted atazanavir plus FTC/TDF in treatment-naive adults with HIV-1
NL-OMON39337Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing EVG/FTC/TDF/GS-9350 regimen with Ritonavir-boosted atazanavir plus FTC/TDF (2 arms). Primary endpoints: Virologic response at Week 48 and Safety and tolerability. Started Sep 2010; status: active, not recruiting.
02
Drugs
elvitegraviremtricitabinetenofovir disoproxil fumaratecobicistatatazanavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON39337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39337.